Pay Attention to These Biotechs
You have to like the action in a troika of senior biotech stocks: Gilead (GILD), Amgen (AMGN) and Celgene (CELG), because it shows you these forward-looking companies are still trying to grow and aren't just sitting there, facing patent cliffs and hoping to hold on before taking a real beating.
I like pharma. For some companies like Merck (MRK), you are being paid to wait for new drugs to kick in as the yield's well above average. Other companies like Abbott Labs (ABT) and Covidien (COV) -- two terrific companies -- are breaking into pieces to bring out value. Johnson & Johnson (JNJ) could easily adopt a breaking-up-is-easy-to-do strategy like Abbott and Covidien and create a gigantic spike for patient investors now that a new CEO is in place....351 more words left in this article. To read them, just click below and try Real Money FREE for 14 days.
There’s no substitute for a trading floor to get great ideas, so Jim Cramer created a better one at Real Money and blogs there exclusively. We then added legendary hedge fund manager, Doug Kass, with his exclusive Daily Diary and best investing ideas. Staffed with more than 4 dozen investing pros, money managers, journalists and analysts, Real Money Pro gives you a flood of opinions, analysis and actionable trading advice found nowhere else, and allows you to interact directly with each expert.
Already a Subscriber? Please login.